As the opioid crisis continues, the need for effective pain relief remains while the risk of addiction is still a major threat. While market access struggles have proved to be a challenge for abuse-deterrent formulations, the industry has been hesitant to move forward with innovation in this area. To find a solution, the opportunities and values within the space need to be reevaluated. ExL’s Pain Management Summit, created based off the former annual Human Abuse Liability Summit, will serve as a platform for professionals in the pain industry to discuss the latest trends in analgesic developments, including the newest progress in abuse-resistant technologies, cannabinoids and marijuana for pain management and treatment of abuse disorders, non-opioid pain drugs, and other therapeutics. It will also explore other issues contributing to the ongoing opioid crisis, including opioid guideline myths, inappropriate treatment approaches, and the transition from oxycodone overdoses to fentanyl and heroin overdoses. Participants will leave with the latest insight on the direction the pharmaceutical pain industry is moving in, a new network of professional relationships, and the resources to move forward with novel pain therapeutics.